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Background-—Early rapid declines of kidney function may occur in patients with atherosclerotic renal artery stenosis with
institution of medical therapy. The causes and consequences are not well understood.
Methods and Results-—Patients enrolled in the medical therapy–only arm of the CORAL (Cardiovascular Outcomes With Renal
Artery Lesions) study were assessed for a rapid decline (RD) in estimated glomerular filtration rate (eGFR), defined as a ≥30%
decrease from baseline to either 3 months, 6 months, or both. In the medical therapy–only cohort, eGFR was available in 359
subjects at all time points, the subjects were followed for a median of 4.72 years, and 66 of 359 (18%) subjects experienced an
early RD. Baseline log cystatin C (odds ratio, 1.78 [1.11–2.85]; P=0.02), age (odds ratio, 1.04 [1.00–1.07]; P<0.05), and Chronic
Kidney Disease Epidemiology Collaboration creatinine eGFR (odds ratio, 1.86 [1.15–3.0]; P=0.01) were associated with an early
RD. Despite continued medical therapy only, the RD group had an improvement in eGFR at 1 year (6.9%; P=0.04). The RD and
nondecline groups were not significantly different for clinical events and all-cause mortality (P=0.78 and P=0.76, respectively).
Similarly, renal replacement therapy occurred in 1 of 66 (1.5%) of the RD patients and in 6 of 294 (2%) of the nondecline patients.
The regression to the mean of improvement in eGFR at 1 year in the RD group was estimated at 5.87.1%.
Conclusions-—Early rapid declines in kidney function may occur in patients with renal artery stenosis when medical therapy is
initiated, and their clinical outcomes are comparable to those without such a decline, when medical therapy only is continued. ( J
Am Heart Assoc. 2019;8:e012366. DOI: 10.1161/JAHA.119.012366.)
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R enal artery stenosis (RAS) is a common problem,especially in older people over the age of 70 years.1
Renal dysfunction is commonplace, and there is a strikingly high
rate of adverse cardiovascular events and mortality in patients
with impaired kidney function and renal artery stenosis.2 A
number of studies have evaluated the factors that predict an
improvement in kidney function after renal artery revascular-
ization, commonly measured with estimates of glomerular
filtration rate (GFR).3,4
One such factor is a rapid decline (RD) in kidney
function, and as a result, some authors have suggested that
an RD in kidney function is an indication for stent
revascularization.3,4 The utility of an RD in GFR as an
indication for revascularization in medically managed
patients has risen in importance since 3 randomized trials
have demonstrated that medical therapy without revascu-
larization is the preferred treatment for most patients with
atherosclerotic RAS.5–7
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ORIGINAL RESEARCH
We sought to determine the frequency of RD of kidney
function in medically managed RAS patients and to examine
the clinical outcomes with continued medical therapy. To
perform this analysis, we used data from the CORAL
(Cardiovascular Outcomes With Renal Artery Lesions)5 clinical
trial to evaluate rapid changes in estimated glomerular
filtration rate (eGFR) occurring within the first 6 months of
medical management in patients with RAS.
Methods
Patient Population
CORAL (NCT00081731) is a prospective, international, mul-
ticenter clinical trial that randomly assigned 931 participants
with atherosclerotic RAS who received optimal medical
therapy to stenting versus no stenting. Randomization
occurred from May 2005 through January 2010. Optimal
medical therapy for CORAL, including the use of antihyper-
tensives, antiplatelet therapy, angiotensin receptor blockers,
angiotensin converting enzyme inhibitors, and statins, has
been previously published,5,8 as has the importance of
optimal medical therapy in treating atherosclerotic RAS.9–11
The full CORAL data set is on the National Heart, Lung, and
Blood Institute website (https://biolincc.nhlbi.nih.gov/studie
s/coral/), where investigators can request access to the data.
All enrolling centers obtained institutional review com-
mittee approval and followed institutional and study guide-
lines. All participating subjects provided written informed
consent. The results of the study have been previously
described.5 Patients with RAS of at least 60% were eligible if
they had hypertension while receiving ≥2 antihypertensive
agents or had an eGFR <60 mL/min per 1.73 m2.
Angiograms were analyzed for verification of stenosis by
the Angiography Core Lab for the study at the University of
Virginia.
Study Aim
The current study sought to examine changes in kidney
function within the medical therapy–only group. The primary
aims were to (1) examine factors that predict RD of kidney
function within the first 6 months of medical therapy and (2)
determine the clinical outcomes of patients with early RD of
kidney function.
Estimation of GFR
eGFR was assessed using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) equations at baseline, 3 and
6 months, and every 6 months for the duration of follow-up.12
Rapid Decline
RD was a dichotomous outcome and was defined as a ≥30%
decrease in eGFR from baseline to either 3 months, 6 months,
or both intervals.13 Nondecline (ND) was defined as those
patients who did not demonstrate an RD.
Statistical Analysis
Continuous data were tested for goodness of fit to the normal
distribution using the Shapiro–Wilk test. If not normally
distributed, the log-transformation of the variable was
assessed for normality. Continuous data are presented as
mean SD of the untransformed or log-transformed version
or, if neither were normally distributed, as median with
interquartile range. Categorical data are presented as fre-
quency and percent. Comparisons of continuous data were
evaluated using 2-sample t tests or Wilcoxon rank sum test.
For categorical variables, the chi-square test or, if the
frequency of counts for some factors was low (≤5), Fisher
exact test was used to compare groups. Statistical signifi-
cance was defined as a P<0.05. All analyses were performed
using R software (version 3.0.0) and SAS (version 9.3).
Multiple Variable Models and Longitudinal Analysis
Analysis was performed comparing the RD and ND groups on
each baseline characteristic, one at a time, using ANOVA
adjusting for age and sex. A stepwise logistic regression with
group (RD versus ND) as the outcome was then used to
further identify characteristics significantly related to group
membership. The model was examined for discriminate ability
using area under the curve from receiver operating charac-
teristic analysis and the Hosmer-Lemeshow goodness-of-fit
test to assess model fit.
Clinical Perspective
What Is New?
• Although large randomized studies such as ASTRAL (Angio-
plasty and Stenting for Renal Artery Lesions) and CORAL
(Cardiovascular Outcomes With Renal Artery Lesions) have
demonstrated the noninferiority of best medical therapy to
that of best medical therapy+stenting, physicians still
continue to consider a sudden deterioration of renal
function in a medically managed patient with renal
atherosclerosis as an indication to place a stent.
What Are the Clinical Implications?
• This analysis of the CORAL data set strongly suggests that
best medical therapy (without stenting) should be continued
in such patients.
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Stepwise multivariate linear regression analysis was used
to examine the independent predictors of percentage change
in eGFR at 1-year follow-up and to assess the safety and
clinical benefit of continued medical therapy. The covariates
in the model included reference baseline GFR, rapid decline,
sex, age, urine albumin to creatinine ratio (UACR), and
cystatin C, and were selected by the stepwise method with
the Akaike information criterion. The effect of RD on kidney
function over time was estimated by applying the generalized
linear mixed model with time (continuous variable) as a
random coefficient. In models with an overall significant effect
over time, post hoc tests were performed to determine which
time-related pairs were significant. Bonferroni adjustment was
used to avoid the potential for inflated type I errors. All
multivariable models were tested for interaction between
predictors and were found to be nonsignificant.
Regression to the Mean
We chose to test for regression to the mean (RTM), as it can
lead to overestimation of the treatment effect if not properly
adjusted. The nonparametric empirical likelihood method14
and kernel density estimation15 were applied to assess the
RTM effect on follow-up repeated measurements of eGFR for
both the RD and ND groups. Percentage change in eGFR
within 6 months became the baseline reference value against
which repeated measurements of eGFR were compared.
ANCOVA was used for comparison between the groups
considering the substantial decline in eGFR in the RD group.16
Clinical Event Analysis
The primary outcome was the composite end point defined as
the first occurrence of any secondary end points: cardiovas-
cular or renal death, myocardial infarction, stroke, congestive
heart failure, or progressive renal insufficiency (≥30% decline
in GFR sustained over a period of 6 months) and permanent
renal replacement). All-cause mortality was also evaluated as
an outcome. Events occurring within 6 months, before the
establishment of the RD or ND reference baseline, were
censored. These patients were included in the analysis of RD
and for follow-up events. The time-to-event analysis used the
first event after the 6-month reference baseline.
The predicted probability of the binary occurrence of the
composite end point was calculated using logistic regression
with adjustment for age, sex, baseline log urine albumin-
to-creatinine ratio (LUACR), and baseline log cystatin C.
Receiver operating characteristic was used to summarize the
model performance. Time to event for the composite and
mortality end points was examined using log-rank estimates
to compare the RD and ND groups. Hazard ratios were
calculated using the Cox proportional-hazards model adjusted
for age, sex, and baseline LUACR and cystatin C. Model
diagnostics were performed using the Cox-Snell residual plot
test to check for goodness of fit. The proportional hazards
assumption tests from the R function cox.zph in the survival
package for all the survival models had P>0.05, indicating that
the null hypothesis of proportional hazards was not rejected.
The extended Cox model was used to test for interaction
among model predictors and time. The time-dependent
covariates were generated by building interactions of the
predictors and a function of survival time and were included in
the models. The P values for all time-covariate interactions in
the survival models were >0.05, confirming the null hypoth-
esis assumption of proportional hazards and indicating that
the fitted Cox regression hazard models are adequate.
Results
There were 472 patients randomized to medical therapy only in
the CORAL clinical trial. For this analysis of the medical
therapy–only cohort, eGFR was available in 359 subjects at all
relevant time points (baseline, 3 and 6 months, and 1 year).
Patients who did not have all estimates relative to determining
their decline status were excluded: CKD-EPI creatinine eGFR at
baseline, 3 or 6 months, and 1 year. Sensitivity analysis was
performed and confirmed that the cohort of patients with
missing data was comparable to patients without missing data
on baseline characteristics (Table S1). Analyzable subjects
were followed for a median of 4.72 (interquartile range, 2.03)
years. The average age was 699 years, 49% were male, and
7% were Hispanic/Latino. The baseline eGFR was 5821 mL/
min, and the median UACR was 20.766.5 lg/mg. The
average systolic blood pressure was 15023 mm Hg, and
diastolic blood pressure was 7813 mm Hg.
Figure 1. CKD-EPI eGFR of subjects with rapid decline from
baseline to1 year. Rapiddeclinewithin 6 months contains 3mutually
exclusive groups: decline at 3 months only, decline at 6 months only,
and decline at both 3 and 6 months. MeanSE at each time period
are given. CKD-EPI indicates Chronic Kidney Disease Epidemiology
Collaboration; eGFR, estimated glomerular filtration rate.
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RD and ND Groups
In the medical therapy–only cohort of CORAL, 66 of 359 (18%)
subjects experienced an early RD. We identified 3 mutually
exclusive groups: 3-month decline only (n=22), 6-month
decline only (n=26), or decline at both 3 and 6 months (n=18)
(Figure 1). All other subjects, those without a decline in eGFR
≥30%, were classified as nondecline (293/359; 82%). The
mean percentage change of eGFR from baseline to within 6
months for the RD group was 40.07.7% and 7.015.8%
for the ND group.
Factors That Predict RD of eGFR
The RDandNDgroupswere very similar asmeasured by baseline
characteristics, including demographic, physical examination,
laboratory values, risk factors, and medication use (Table 1).
UACR was the only univariate factor that was significantly
Table 1. Baseline Clinical Characteristics of Patients With an
Early Rapid Decline of Kidney Function (>30% Within 6 Months
of Baseline) and Those Without an Early Rapid Decline of
Kidney Function
Baseline Characteristics*
Rapid
Decline
(n=66)
No Rapid
Decline
(n=294)
P
Value
Demographic/physical examination
Age, y 71.57.8 69.59.3 0.07
Male sex 33 (50) 143 (49) 0.89
Black race 5 (8) 18 (6) 0.59
Hispanic/Latino 3 (5) 16 (5) >0.99
Height, inches 65.83.8 66.04.2 0.72
Weight, lb 178.242.5 176.834.6 0.80
BMI, kg/m2 29.96.9 29.55.9 0.67
Systolic BP, mm Hg 154.223.9 148.622.7 0.08
Diastolic BP, mm Hg 77.415.4 78.012.7 0.77
Laboratory values (assessed by core lab)
Creatinine, mg/dL 1.20.5 1.20.5 0.94
Cystatin C, mg/L 1.40.5 1.30.5 0.16
MDRD-eGFR, mL/min
per 1.73 m2
62.223.1 61.222.9 0.74
CKD-EPI creatinine formula 58.921.6 58.221.2 0.80
CKD-EPI cystatin C formula 57.923.5 61.722.3 0.22
CKD-EPI creatinine-cystatin
C formula
58.722.7 60.021.9 0.68
Urine albumin to creatinine
ratio, lg/mg†
3.81.8 3.31.6 0.05
Urine albumin to creatinine
ratio, lg/mg‡
29.7131.1 18.643.4 0.03
Risk factors/indications
Peripheral vascular disease 27 (41) 151 (52) 0.13
Hyperlipidemia 58 (88) 265 (92) 0.34
Prior myocardial infarction 20 (31) 87 (30) 0.88
Prior transient ischemic
accident
16 (24) 56 (19) 0.40
Angina 8 (13) 38 (15) 0.84
Cardiovascular disease 38 (62) 169 (62) >0.99
Diabetes mellitus 26 (39) 98 (33) 0.39
Congestive heart failure 6 (9) 46 (16) 0.24
Chronic kidney disease 40 (61) 185 (63) 0.78
CKD stage
Mild 28 (42) 95 (33) 0.12
Moderate 26 (39) 131 (45) 0.49
Severe 5 (8) 16 (5) 0.27
Renal dysfunction 20 (31) 70 (24) 0.27
Continued
Table 1. Continued
Baseline Characteristics*
Rapid
Decline
(n=66)
No Rapid
Decline
(n=294)
P
Value
Smoking 17 (26) 89 (30) 0.55
Premature coronary
artery disease
15 (27) 95 (38) 0.16
Bilateral disease 12 (24) 38 (21) 0.70
% Stenosis 66.812.6 67.811.8 0.59
Medication use
Diuretic 27 (44) 119 (45) >0.99
b-blocker 36 (57) 127 (48) 0.21
a-blocker 13 (20) 40 (14) 0.25
ab-blocker 5 (8) 29 (10) 0.65
Calcium-channel blocker 28 (51) 97 (40) 0.17
Renin inhibitor 1 (2) 2 (1) 0.46
Vasodilator 3 (5) 9 (3) 0.47
Nitrate 11 (17) 56 (20) 0.61
ACEI/ARB 59 (92) 232 (90) 0.81
Antiplatelet agent 41 (73) 172 (74) 0.87
Statin 38 (68) 149 (66) 0.88
Total all medications 2.21.5 2.11.6 0.40
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BMI, body mass index (weight in kilograms divided by the square of the height in
meters); BP, blood pressure; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney
Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD,
modified diet in renal disease.
*Data are expressed as the meanSD or number (percentage). Comparisons were
evaluated using a 2-sample t test for continuous data or Fisher’s exact test for
categorical data.
†Urine albumin-to-creatinine ratio (UACR) is measured as the log of UACR.
‡UACR is measured as median interquartile range.
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different between the RD and ND groups (29.7131.1 versus
18.643.4 lg/mg, respectively; P=0.03).
Stepwise logistic regression was then employed to identify
factors associated with an RD within 6 months. The overall
model was significant with adjustment for age and sex, while
stepwise selection, forcing in age and sex, was used to
identify other factors to include in the model. The baseline
factors log of cystatin C (odds ratio, 1.78 [1.11–2.85];
P=0.02,), age (odds ratio, 1.04 [1.00–1.07]; P<0.05), and
CKD-EPI creatinine eGFR (odds ratio, 1.86 [1.15, 3.0]; P=0.01)
were found to be significant predictors of an early RD. To
place this in context, a 1-SD increase in the log of cystatin C
was associated with a 78% increase in the odds of experi-
encing a rapid decline in eGFR within 6 months, and a 1-SD
increase in baseline eGFR was related to an 86% increase of
odds for a rapid decline. LUACR, in the logistic regression
analysis, was marginally significant (P=0.07) but was not
included in the final model (Figure 2). The appropriateness of
the model was validated by area under the curve (0.66) from
receiver operating characteristic analysis and the Hosmer-
Lemeshow goodness-of-fit test (P=0.51).
Effect of Early RD on eGFR at 1 Year and Later
The relationship between an early RD and kidney function at 1
year, measured as percentage change of eGFR from the
6-month reference baseline, was examined (Table 2). An early
RD, despite continued medical therapy only, was associated
with an improvement in eGFR at 1 year (6.9%; P=0.04), as was
baseline LUACR (1.8%; P=0.007), and baseline cystatin C
(14.2%; P<0.001). In this regard, the presence of an early RD
accounted for a subsequent 6.9% improvement in eGFR at 1
year compared with the ND group. Overall, baseline LUACR
predicted a 1.8% decline in eGFR at 1 year per 1-unit increase
in LUACR, while baseline cystatin C predicted a 14.2%
increase in eGFR per 1-unit increase in cystatin C. The RD
group also had a greater improvement in eGFR at 1 year
compared with the ND group by analysis of least square
means (11.93.0% versus 5.01.2%; P=0.04).
A generalized linear mixed model was used to estimate the
longitudinal effect of an RD to 5-year follow-up (Figure 3A and
3B). Based on the observed eGFR, the groups were similar at
baseline, but the RD group had worse renal function from the
onset of decline within 6 months and through 5-year follow-up
compared with the ND group (P<0.001; Figure 3A, Figure S1).
However, subjects with RD had significant and sustained
improvement in percentage change of eGFR from the reference
baseline (within 6 months) that was maintained through 5-year
follow-up compared with the ND group (P<0.001; Figure 3B).
Clinical Outcomes of Patients With and Without
an Early RD in eGFR
Comparisons of the RD and ND groups using log-rank test were
not significantly different for composite end point outcomes
and all-cause mortality (P=0.78 and P=0.76, respectively).
Occurrence of an RD in eGFR did not have a higher hazard ratio
for clinical events or mortality in Cox proportional hazard
models adjusted for age, sex, and baseline LUACR (respectively,
0.93; 95% CI, 0.56–1.54; P=0.77; and 0.74; 95% CI, 0.34–1.60;
P=0.45) (Figure 4A and 4B). Similarly, renal replacement
therapy occurred in 1 of 66 (1.5%) of the RD patients and in 6
of 294 (2%) of the ND patients. In contrast, in the adjusted Cox
models, age and baseline LUACR represented a significant
hazard for clinical events. Overall, the suitability of the adjusted
Cox models was confirmed using the log likelihood ratio test
(P<0.001 and P=0.0002, respectively.)
Other clinical outcomes evaluated over time, by RD status,
were systolic blood pressure, diastolic blood pressure, and
LUACR (Figure S2A through S2C). Longitudinal analysis using
mixed model repeated measures, with time considered as a
categorical factor, demonstrated lower systolic blood pres-
sure for subjects with RD at 6-month follow-up (P=0.012) but
was not different at other time points (P=0.19, Figure S2A).
Figure 2. Baseline predictors of rapid decline in CKD-EPI eGFR
within 6 months. Odds ratios with CIs from logistic regression.
The odds ratios for cystatin C and CKD-EPI Cr eGFR are shown per
1-SD-unit increase in each factor. CKD-EPI indicates Chronic
Kidney Disease Epidemiology Collaboration; eGFR, estimated
glomerular filtration rate.
Table 2. Predictors of 1-Year GFR Percentage Change After
Rapid Decline Using Multivariable Linear Regression Adjusted
for Age and Sex
Predictors Estimate Std. Error P Value
CKD-EPI Cr eGFR (reference value)* 0.132 0.07 0.055
Rapid decline (yes) 6.94 3.43 0.043
Sex (male) 2.66 2.01 0.186
Age, y 0.10 0.11 0.358
Albumin-to-creatinine ratio (log) 1.81 0.67 0.007
Cystatin C (log) 14.22 3.22 <0.001
CKD-EPI indicates Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated
glomerular filtration rate.
*Within 6 months decline in eGFR.
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Diastolic blood pressure was significantly lower in the RD
group when all follow-up times were considered (P=0.04) and
was significant at 6 months (P<0.001; Figure S2B). LUACR
was higher at baseline in the RD subjects (P=0.042) but was
not different thereafter in follow-up (P=0.95; Figure S2C).
Regression to the Mean
In the RD group, CKD-EPI e-GFR increased by 15.916.5% at
1 year. The RTM effect was estimated at 5.87.1%; therefore,
after adjusting for the RTM effect, the 1-year CKD-EPI e-GFR
increased by 10.118.0%. In the ND group, CKD-EPI e-GFR
Figure 3. Longitudinal effect of rapid decline on CKD-EPI eGFR. A, Demonstrates that the observed eGFR for both the rapid decline and
nondecline groups are similar at baseline and the dashed line for the whole population trends with the nondecline group. Overall, the rapid
decline group had worse renal function from the onset within 6 months through 5 years of follow-up than the nondecline group (P<0.001). B, The
rapid decline group had consistent significant improvement in eGFR over 5 years (P<0.001) and at each time period compared with the
nondecline group. MeansSE at each time period are compared using the Student t test. CKD-EPI indicates Chronic Kidney Disease
Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.
Figure 4. Kaplan–Meier survival curves and Cox proportional hazards models adjusted by age, sex, and
baseline albumin to creatinine ratio (log) for composite clinical outcomes and all-cause mortality. A,
Compares decline status survival curves that are not significant by the log-rank test for the composite end
points (P=0.78), and a rapid decline in eGFR did not convey a higher hazard for occurrence of clinical events
using Cox proportional hazards model. B, The rapid decline group was not significantly different by log-rank
test (P=0.76), and had a similar hazard ratio for all-cause mortality compared with the nondecline group.
eGFR indicates estimated glomerular filtration rate.
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increased by 4.219.3% and no RTM effect was detected
(Figure 5). The difference between the adjusted CKD-EPI
eGFR percentage change in the RD group and the unadjusted
eGFR in the ND group was significant (P<0.001).
Discussion
In the current study, we identified that early RD in kidney
function was commonplace during the institution of aggres-
sive medical management of patients with atherosclerotic
RAS. By multivariable analysis, age and baseline kidney
function were indicative of those likely to experience an early
RD. Interestingly, though, patients who experienced this
appeared to do reasonably well, and in fact had an improve-
ment in kidney function by 1 year that was sustained over
5 years of follow-up. Thus, the current analysis indicates that
early RD in kidney function for patients with atherosclerotic
RAS after the institution of medical therapy are relatively
common. Furthermore, the long-term clinical outcomes are
similar, with no difference in mortality or event-free survival,
with continued medical therapy only.
Recent studies, including ASTRAL, STAR (stent placement
and blood pressure and lipid lowering for the prevention of
renal dysfunction caused by atherosclerotic ostial stenosis of
the renal artery), and CORAL have demonstrated equivalent
results with the use of medical therapy alone when compared
with stenting and medical therapy for patients with
atherosclerotic RAS. Previous studies suggested that patients
who were treated medically and experienced an early RD in
kidney function were likely to experience an improvement in
kidney function if they underwent stent treatment. Our
current analysis now adds that patients who continue medical
therapy alone often experience an improvement in kidney
function.17 These results are useful in that they should
prevent unnecessary stenting in this patient population.
Simply, an early RD in renal function with medical treatment
may not be an indication for stenting.
Furthermore, it is important to note the effect of regression
to the mean in this analysis. Regression to the mean is a
statistical phenomenon wherein more extreme values will
move closer to the mean over time upon remeasurement. In
this analysis, the RD group represents the extreme values that
are more likely to regress toward the mean and experience an
improvement in kidney function on remeasurement, even in
the absence of a change in treatment.
A limitation of the current work is that there were few
patients in the study who had advanced kidney disease, stage
IV or greater. Thus, in these subjects, no conclusion should be
made.
Conclusion
The current analysis demonstrates that early rapid declines in
kidney function occur in some patients with RAS when
medical therapy is initiated and that their clinical outcomes
are comparable to those without such a decline when treated
with medical therapy only.
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SUPPLEMENTAL MATERIAL 
 
 
Table S1. Comparison of Patients with Incomplete Data with Studied Patients. 
 
Baseline Characteristics* Not Missing 
(n=359) 
Missing 
(n=113) 
P-value 
Demographic/physical examination    
Age (yr) 69.9± 9.0 68.4±8.5 0.11 
Male sex 176(49) 51(45) 0.52 
Black race 23(6) 11(10) 0.30 
Hispanic/Latino 19(5) 13(12) 0.03 
Height (in) 66.0± 4.2 65.6±4.2 0.40 
Weight (lb) 177.0± 36.1 174.6±40.3 0.58 
BMI (kg/m2) 29.5±5.9 29.4±5.9 0.87 
Systolic BP (mmHg) 149.7± 23.0 152.7±22.9 0.22 
Diastolic BP (mmHg) 77.9± 13.3 80.6±13.8 0.07 
Laboratory values (assessed by core 
lab) 
   
Creatinine (mg/dl)  1.2±0.5 1.2±0.4 0.97 
Cystatin C (mg/L) 1.3±0.5 1.3±0.5 0.24 
MDRD-eGFR (ml/min per 1.73 m2) 61.4±22.9 60.1±23.4 0.66 
CKD-EPI creatinine formula  58.3±21.3 57.4±21.6 0.73 
CKD-EPI cystatin C formula  61.0±22.6 57.7±23.0 0.22 
CKD-EPI Creatinine- cystatin C formula  59.7±22.1 57.5±22.8 0.41 
Urine albumin to creatinine ratio 
(ug/mg)** 
3.4±1.6 3.7±1.7 0.09 
Risk factors/indications    
Peripheral vascular disease 177(50) 61(55) 0.38 
Hyperlipidemia 322(91) 97(87) 0.21 
Prior myocardial infarction 106(30) 34(31) 0.91 
Prior transient ischemic accident 72(20) 19(18) 0.68 
Angina 45(14) 12(13) >0.99 
Cardiovascular disease 206(62) 69(67) 0.41 
Diabetes mellitus 123(34) 38(36) 0.82 
Congestive heart failure 51(14) 18(17) 0.54 
Chronic kidney disease 225(63) 70(62) 0.91 
CKD Stage                             Mild 123(34) 33(30) 0.42 
                                               Moderate 157(44) 42(38) 0.32 
                                               Severe 21(6) 5(5) 0.81 
Renal Dysfunction 90(25) 28(25) >0.99 
Smoking 105(29) 45(41) 0.03 
Premature Coronary Artery Disease 110(36) 33(36) >0.99 
Bilateral disease 50(21) 16(21) >0.99 
% Stenosis 75.7±10.8 76.2±10.4 0.65 
Medication Use    
Diuretic 145(44) 40(39) 0.42 
-Blocker 162(50) 52(51) 0.82 
-Blocker 53(15) 18(17) 0.76 
-Blocker 34(10) 12(11) 0.71 
Calcium-channel blocker 125(42) 31(33) 0.15 
Renin inhibitor 3(1) 0(0) >0.99 
Vasodilator 12(3) 9(8) 0.06 
Nitrate 67(20) 20(20) >0.99 
ACE/ARB 165(50) 44(44) 0.26 
Antiplatelet agent 212(74) 61(66) 0.14 
Statin 186(66) 61(68) >0.99 
Total all medications 2.1±1.6 2.0±1.6 0.52 
*Data are expressed as the mean ± SD or number (percentage).  Comparisons were evaluated  
using two sample t-test for continuous data or Fisher’s exact test for categorical data. 
**Urine albumin to creatinine ratio (UACR) is measured as the log of UACR 
yr, year; in, inch; lb, pound; BMI, body mass index ((weight in kilograms divided by the square of the height in meters); 
BP, blood pressure; MDRD , Modified Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration; eGFR, estimated glomerular filtration rate; CKD, Chronic kidney disease; ACE, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; β-Blocker, beta adrenergic blocker; -Blocker, alpha blocker; and 
-Blocker, alpha-beta blocker. 
 
 
Figure S1. Rapid decline patients CKD-EPI eGFR longitudinal response.   
 
 
The observed trend of longitudinal improvement in eGFR after six-months for patients 
experiencing rapid decline demonstrates stable renal function out to 3-years follow-up 
and beyond. 
 
Figure S2 a-c. Longitudinal effect of rapid decline status on clinical outcomes.  
 
 
Graphs represent the following: a) systolic blood pressure (mmHg); b) diastolic blood pressure 
(mmHg); and c) albumin to creatinine ratio (log).  Mean ± SE for baseline through 5-year follow-
up are given.  
 
